

**ESOPHAGOGASTRIC
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION**

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 30th, 2016

TIME: 13:30 – 15:00 pm

CHAIRS: DR. REBECCA WONG & DR. CHRISTIAN KOLLMANSBERGER

-
- 13:30 WELCOME AND INTRODUCTION **DR. R. WONG / DR. C. KOLLMANSBERGER**
- ACTIVE TRIALS FOR UPDATE/DISCUSSION
- 13:35 **GA.1 (TOP GEAR):** A RANDOMIZED PHASE III TRIAL OF PREOPERATIVE CHEMORADIOTHERAPY VERSUS PREOPERATIVE CHEMOTHERAPY FOR RESECTABLE GASTRIC CANCER **DR. J. RINGASH**
- APPROVED TRIALS IN DEVELOPMENT
- 13:50 **GA.3 (INTEGRATE II)** - A RANDOMIZED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF REGORAFENIB IN REFRACTORY ADVANCED OESOPHAGO-GASTRIC CANCER (AOGC) **DR. T. ALCINDOR**
- CONCEPTS IN DEVELOPMENT
- 14:10 A SINGLE ARM PHASE II TRIAL OF NEOADJUVANT PEMBROLIZUMAB + CHEMORADIATION (CROSS PROTOCOL) FOR ESOPHAGEAL ADENOCARCINOMA **DR. J. MONZON**
- 14:20 A RANDOMIZED PHASE II TRIAL OF ADJUVANT DURVALUMAB (MEDI4736) FOLLOWING ESOPHAGECTOMY FOR ESOPHAGEAL ADENOCARCINOMA **DR. G. DARLING**
- 14:30 IXO IN FIRST LINE METASTATIC (HER2 -) GASTRIC AND GEJ ADENOCARCINOMA **DR. J. SPRATLIN**
- 14:40 PILOT RCT NEOADJUVANT CT VS CRT IN ESOPHAGUS (POWERRANGER) **DR. G. BUDUHAN**
- 14:50 INTERGROUP TASK FORCE UPDATE **DR. R. WONG & Dr. C. KOLLMANSBERGER**
- 15:00 CLOSING REMARKS